Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation

Next Previous
X
Search
Trial Profile

Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Etoposide; Idarubicin; Pegfilgrastim; Tretinoin
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 12 Dec 2023 Results assessing the genomic landscape and leukemogenic trajectories in a large cohort of NPM1mut AML pts and to investigate its prognostic and predictive impact on outcome, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 13 Dec 2022 Final results presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Primary endpoint (Overall survival (OS) has not been met according to results presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top